RedHill acquires Ferring's Rebyota and Clenpiq rights
Asset purchase. This is a purchase of assets, contracts or a business line, not of a whole company.
Buyer
RedHill Biopharma Ltd
Description
RedHill Biopharma announced the acquisition of exclusive global and U.S. commercialization rights to Ferring's Rebyota and Clenpiq. The deal, valued at $12 million upfront plus potential royalties, is part of RedHill's strategic repositioning in the gastrointestinal market. The drugs generated approximately $37.5 million in 2025 net sales, enhancing RedHill's commercial prospects and liquidity.
Other recent acquisitions in Healthcare and Science And Engineering
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Wandercraft acquires Ekso Bionics for robotics synergy (October 3, 2026)
- SpyGlass Pharma, Inc. Acquires Santen Holdings US, Inc. (October 1, 2026)
- Lifecore Biomedical, Inc. Enters Merger Agreement with Lifecore Inc. (September 28, 2026)
- Apotex acquires Talicia from RedHill for $18M, $18M (August 31, 2026)
- OrthoPediatrics acquires SpineCorporation, enhancing reach (July 27, 2026)
- Yarrow Bioscience completes merger with VYNE Therapeutics (July 27, 2026)
Who to call at RedHill Biopharma Ltd, and when
When RedHill Biopharma Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day RedHill Biopharma Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at RedHill Biopharma Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at RedHill Biopharma Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment RedHill Biopharma Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.